Injectable in vivo crosslinking materials for use as soft tissue fillers

Patent metadata

Field	Value
Publication number	US-12016969-B2
Application number	US-202117165485-A
Country	US
Kind code	B2
Filing date	Feb 2, 2021
Priority date	Feb 4, 2020
Publication date	Jun 25, 2024
Grant date	Jun 25, 2024

Abstract

Described herein are injectable in vivo crosslinking materials for use as soft tissue filler comprising (a) a reactive multi-arm polymer that comprises a plurality of hydrophilic polymeric arms, at least a portion of the hydrophilic polymeric arms comprising one or more reactive end groups and (b) a multifunctional compound that comprises functional groups that are reactive with the reactive end groups of the reactive multi-arm polymer. Also described herein are systems and methods that are based on such materials.

First claim

What is claimed is:

1. An injectable in vivo crosslinking material for use as soft tissue filler comprising (a) a reactive multi-arm polymer that comprises a plurality of hydrophilic polymeric arms, the hydrophilic polymer arms comprising poly(2-methyl-2-oxazoline) arms, at least a portion of the hydrophilic polymeric arms comprising one or more reactive end groups and (b) a multifunctional compound that comprises functional groups that are reactive with the reactive end groups of the reactive multi-arm polymer.

2. The injectable in vivo crosslinking material of claim 1 , wherein the hydrophilic polymeric arms further comprises a hydrolysable ester group.

3. The injectable in vivo crosslinking material of claim 1 , wherein the reactive end groups are electrophilic groups and the functional groups are nucleophilic groups.

4. The injectable in vivo crosslinking material of claim 1 , wherein the reactive end groups are selected from N-hydroxysuccinimide esters, imidazole esters, imidizole carboxylates and benzotriazole esters.

5. The injectable in vivo crosslinking material of claim 1 , wherein the functional groups are selected from amine groups and thiol groups.

6. The injectable in vivo crosslinking material of claim 1 , wherein the multifunctional compound comprises a polyamine.

7. The injectable in vivo crosslinking material of claim 1 , wherein the reactive end groups of the reactive multi-arm polymer and the functional groups of the multifunctional compound react with one another via an amide coupling reaction.

8. The injectable in vivo crosslinking material of claim 7 , wherein the reactive end groups of the reactive multi-arm polymer comprise carboxyl groups, wherein the functional groups of the multifunctional compound comprise amine groups, and wherein the injectable in vivo crosslinking material further comprises a carbodiimide coupling agent.

9. The injectable in vivo crosslinking material of claim 1 , wherein the injectable in vivo crosslinking material is moldable in situ.

10. A system for forming the injectable in vivo crosslinking material in accordance with claim 1 , comprising (a) a first composition comprising the reactive multi-arm polymer and (b) a second composition comprising the multifunctional compound.

11. The system of claim 10 wherein the first composition, the second composition, or both the first composition and the second composition comprise a therapeutic agent, an imaging agent, or both.

12. The system of claim 10 , comprising a first syringe barrel containing the first composition and a second first syringe barrel containing the second composition.

13. The system of claim 10 , further comprising a delivery device configured to deliver a mixture of the first composition and the second composition into epidermis, dermis, and/or subcutaneous tissue of a patient.

14. The system of claim 13 , wherein the delivery device comprises a first reservoir containing the first composition, a second reservoir containing the second composition, and a needle that is configured to inject the injectable in vivo crosslinking material into epidermis, dermis, and/or subcutaneous tissue of a patient.

15. The system of claim 13 , wherein the injectable in vivo crosslinking material is moldable in situ.

16. A method comprising injecting the injectable in vivo crosslinking material in accordance with claim 1 into epidermis, dermis, and/or subcutaneous tissue of a patient.

17. The method of claim 16 , wherein the injectable in vivo crosslinking material is injected beneath a skin defect that is lower or deeper than surrounding skin.

18. The method of claim 16 , wherein in vivo crosslinking material is molded by a healthcare provider within the patient after injection.

Assignees

• Boston Scient Scimed Inc

Inventors

• Delaney Jr Joseph T
• Boden Mark W
• Murphy John
• Molnar Viktoria
• Dyndikova Tatyana
• Zipp Allison
• Kolste Kolbein K

Classifications

• A61L27/50

  Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

• A61L27/3839

  characterised by the site of application in the body (materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60) · CPC title

• A61L27/18 Primary

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds · CPC title

• A61L2430/34

  for soft tissue reconstruction · CPC title

• A61L2400/06

  Flowable or injectable implant compositions · CPC title